ArticleClinical, cosmetic and investigational dermatology2025
Successful Treatment of Severe Nail Lichen Planus with Janus Kinase 1 Inhibitor Abrocitinib.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of JAK Inhibitors in Lichen Planus: A Systematic Review of the Available Clinical Evidence.Mediators of inflammation · 2026Pooled it
- Refractory nail lichen planus treated successfully with the Janus kinase 1 inhibitor abrocitinib: A case report.The Journal of international medical research · 2026Article
- Therapeutic Outcomes of Janus Kinase Inhibitors in Refractory Nail Lichen Planus: A Systematic Review.Cureus · 2026Review
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology.Medicina (Kaunas, Lithuania) · 2026Review
- Effectiveness of Abrocitinib in Atopic Dermatitis Presenting with Hand-Foot Eczema and Nail Dystrophy: A Case Report.Clinical, cosmetic and investigational dermatology · 2026Article
- Successful Treatment of Childhood Nail Lichen Planus with Ruxolitinib Cream: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- Successful Treatment of Nail Lichen Planus by the Janus Kinase 1 Upadacitinib and Literature Review.Clinical, cosmetic and investigational dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nail lichen planus (NLP) is a chronic inflammatory disease that presents a significant therapeutic challenge. It can progress rapidly, leading to impaired nail morphology and function. Currently, there is no established standard therapy due to limited efficacy or potential for significant adverse reactions. In this report, we present a case of very severe NLP successfully treated with the Janus kinase 1 (JAK1) inhibitor abrocitinib, with no associated discomfort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.